A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Urothelial Carcinoma
Related studies linked through entity extraction aliases.
ARON-2 Study-Multicentric International Retrospective Study
- Status
- RECRUITING
- Phase
- N/A
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
- Status
- TERMINATED
- Phase
- PHASE1
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
- Status
- RECRUITING
- Phase
- PHASE2
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2
RTX-224 Monotherapy in Patients With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
- Status
- COMPLETED
- Phase
- PHASE3
Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
- Status
- RECRUITING
- Phase
- PHASE3
Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population
- Status
- COMPLETED
- Phase
- NA
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
- Status
- TERMINATED
- Phase
- N/A
Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.
- Status
- UNKNOWN
- Phase
- N/A
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2